Provided by Tiger Trade Technology Pte. Ltd.

NRX Pharmaceuticals Inc.

2.28
+0.18008.57%
Post-market: 2.25-0.0300-1.32%19:18 EST
Volume:1.09M
Turnover:2.50M
Market Cap:67.50M
PE:-0.97
High:2.41
Open:2.12
Low:2.11
Close:2.10
52wk High:6.01
52wk Low:1.21
Shares:29.61M
Float Shares:21.83M
Volume Ratio:1.81
T/O Rate:4.99%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-2.3483
EPS(LYR):-2.3605
ROE:-682.61%
ROA:-97.83%
PB:-2.62
PE(LYR):-0.97

Loading ...

NRX Pharmaceuticals Inc: Believes That Its Current Cash Position Will Support Operations Into 2026

THOMSON REUTERS
·
Aug 18

Press Release: NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) Reports Second Quarter 2025 Financial Results and Provides Corporate Update

Dow Jones
·
Aug 18

NRX Pharmaceuticals Inc Files for Offering of 3.9 Mln Shares of Common Stock to Some Accredited Investors at $1.65 per Share- SEC Filing

THOMSON REUTERS
·
Aug 18

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Aug 16

NRX Pharmaceuticals Secures Fast Track Designation from FDA for NRX-100, Aiming to Combat Suicidal Depression

Reuters
·
Aug 15

NRX Pharmaceuticals Inc. Announces Second Quarter 2025 Financial Results Release

Reuters
·
Aug 14

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Aug 13

NRx Pharmaceuticals, Inc. (NASDAQ:NRXP) to Report Second Quarter 2025 Financial Results on August 14, 2025

GlobeNewswire
·
Aug 12

NRX Pharmaceuticals Is Maintained at Buy by D. Boral Capital

Dow Jones
·
Aug 11

NRX Pharmaceuticals Granted FDA Fast Track Designation for NRX-100 to Address Suicidal Ideation in Depression Patients

Reuters
·
Aug 11

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Granted FDA Fast Track Designation for NRX-100 for Suicidal Ideation in Patients With Depression, Including Bipolar Depression

THOMSON REUTERS
·
Aug 11

NRX Pharmaceuticals Inc expected to post a loss of 20 cents a share - Earnings Preview

Reuters
·
Aug 08

NRX Pharmaceuticals Inc. Receives Final Regulatory Approval from Florida's AHCA to Close Dura Medical Acquisition

Reuters
·
Aug 08

Hope Therapeutics, Inc. and NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announce Receipt of Final Clearance to Proceed to Closing of Dura Medical Acquisition From Florida's Agency for Health Care Administration (Ahca)

THOMSON REUTERS
·
Aug 08

NRX Pharmaceuticals Inc. Files Citizen Petition with FDA to Remove Toxic Preservative from Ketamine Products

Reuters
·
Aug 04

NRX Pharmaceuticals, Inc. (Nasdaq:Nrxp) Announces Filing of a Citizen Petition With the US Food and Drug Administration Seeking Removal of Benzethonium Chloride From Ketamine Products

THOMSON REUTERS
·
Aug 04

NRX Pharmaceuticals: Seeking Labeled Indication to Use Ketamine to Treat Suicidal Depression Through National Priority Voucher Program

THOMSON REUTERS
·
Aug 04

NRX Pharmaceuticals Inc. CEO to Participate in Fireside Chat at BTIG Virtual Biotech Conference

Reuters
·
Jul 29

HOPE Therapeutics, Subsidiary of NRX Pharmaceuticals, to Acquire 49% Stake in Cohen and Associates Clinic

Reuters
·
Jun 26

NRx Pharmaceuticals Files for FDA Commissioner's National Priority Voucher for Innovative Ketamine Formulation, Anticipates Approval Decision by Year-End 2025

Reuters
·
Jun 23